TY  - GEN
AU  - Chen,Qiao-Hong
AU  - Chen,Qiao-Hong
TI  - Anticancer Agents : Design, Synthesis and Evaluation
SN  - books978-3-0365-0141-3
PY  - 2021///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - benzofurans
KW  - chemical synthesis
KW  - cytotoxic properties
KW  - HeLa
KW  - MOLT-4
KW  - K562
KW  - anticancer
KW  - anti-neuroinflammation
KW  - coumarin
KW  - dihydroartemisinin
KW  - flavonoids
KW  - allene
KW  - E-stereoselective
KW  - regioselective
KW  - anti-cancer activity
KW  - cyanopyridone
KW  - substituted pyridine
KW  - pyridotriazine
KW  - pyrazolopyridine
KW  - thioxotriazopyridine
KW  - anticancer activity
KW  - HepG2
KW  - antitumor activity
KW  - computational docking
KW  - MDM2-p53 interaction
KW  - xanthones
KW  - yeast-based assays
KW  - estrone derivatives
KW  - hydrazine
KW  - N-substituted pyrazoline
KW  - anti-ovarian cancer
KW  - topoisomerase II inhibitor
KW  - kinase inhibitor
KW  - antiproliferative agent
KW  - urea
KW  - synthesis
KW  - antiproliferative activity
KW  - apoptosis
KW  - indoleamine 2,3-dioxygenase
KW  - inhibitor
KW  - anti-tumor
KW  - immune modulation
KW  - tryptophan metabolism
KW  - taxoids
KW  - βIII-tubulin
KW  - P-glycoprotein
KW  - drug resistance
KW  - thiopene
KW  - thienopyrimidinone
KW  - thiazolidinone
KW  - breast cancer
KW  - benzofuran-pyrazole
KW  - nanoparticles
KW  - cytotoxic activity
KW  - PARP-1 inhibition
KW  - 3,6-dibromocarbazole
KW  - 5-bromoindole
KW  - carbazole
KW  - actin
KW  - migration
KW  - Thienopyrimidine
KW  - Pyrazole
KW  - PI3Kα inhibitor
KW  - quinazolin-4(3H)-one
KW  - quinazolin-4(3H)-thione
KW  - Schiff base
KW  - antioxidant activity
KW  - DFT study
KW  - ortho-quinones
KW  - beta-lapachone
KW  - tanshione IIA
KW  - PI3Ks
KW  - PI3Kδ inhibitors
KW  - 2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide
KW  - anticancer agents
KW  - protein-protein interactions
KW  - virtual screening
KW  - mimetics
KW  - drug discovery
KW  - bivalency
KW  - polyvalency
KW  - antitumor
KW  - cell cycle
KW  - ovarian cancer
KW  - P-MAPA
KW  - IL-12
KW  - TLR signaling
KW  - inflammation
KW  - chemoresistance
KW  - 4-(pyridin-4-yloxy)benzamide
KW  - 1,2,3-triazole
KW  - c-Met
KW  - natural product
KW  - anticancer agent
KW  - zampanolide
KW  - Talazoparib
KW  - PARP inhibitor
KW  - prodrug
KW  - o-nitro-benzyl
KW  - photoactivatable protecting groups
KW  - salinomycin
KW  - overcoming drug resistance
KW  - tumor specificity
KW  - synergy
KW  - 5-fluorouracil
KW  - gemcitabine
KW  - amides/esters
KW  - colchicine analogs
KW  - thiocolchicine
KW  - colchiceine
KW  - antimitotic agents
KW  - hydrates
KW  - dihydropyranoindole
KW  - HDAC inhibitors
KW  - neuroblastoma
KW  - aromatase
KW  - MCF-7
KW  - NIH3T3
KW  - benzimidazole
KW  - triazolothiadiazine
KW  - docking
KW  - ADME
KW  - organosilicon compounds
KW  - SILA-409 (Alis-409)
KW  - SILA-421 (Alis-421)
KW  - multidrug resistance (MDR) reversal
KW  - ABCB1 (P-glycoprotein)
KW  - colon cancer
KW  - colchicine amide
KW  - colchicine sulfonamide
KW  - tubulin inhibitors
KW  - docking studies
KW  - crystal structure
KW  - PROTACs
KW  - protein degradation
KW  - IGF-1R
KW  - Src
KW  - protein kinase
KW  - phenylpyrazolopyrimidine
KW  - enzyme inhibition
KW  - molecular simulation
KW  - androgen receptor
KW  - prostate cancer
KW  - enzalutamide
KW  - apalutamide
KW  - darolutamide
KW  - triple-negative breast cancer
KW  - cytotoxicity
KW  - chrysin analogues
KW  - flavonoid
KW  - anticancer compounds
N1  - Open Access
N2  - This book is a printed edition of the Special Issue entitled "Anticancer Agents: Design, Synthesis and Evaluation" that was published in Molecules. Two review articles and thirty research papers are included in the Special Issue. Three second-generation androgen receptor antagonists that have been approved by the U.S. FDA for the treatment of prostate cancer have been reviewed. Identification of mimics of protein partners as protein-protein interaction inhibitors via virtual screening has been summarized and discussed. Anticancer agents targeting various protein targets, including IGF-1R, Src, protein kinase, aromatase, HDAC, PARP, Toll-Like receptor, c-Met, PI3Kdelta, topoisomerase II, p53, and indoleamine 2,3-dioxygenase, have been explored. The analogs of three well-known tubulin-interacting natural products, paclitaxel, zampanolide, and colchicine, have been designed, synthesized, and evaluated. Several anticancer agents representing diverse chemical scaffolds were assessed in different kinds of cancer cell models. The capability of some anticancer agents to overcome the resistance to currently available drugs was also studied. In addition to looking into the in vitro ability of the anticancer agents to inhibit cancer cell proliferation, apoptosis, and cell cycle, in vivo antitumor efficacy in animal models and DFT were also investigated in some papers
UR  - https://mdpi.com/books/pdfview/book/3445
UR  - https://directory.doabooks.org/handle/20.500.12854/68429
ER  -